Crestor(R) (rosuvastatin), Viagra(R) (sildenafil), Cialis(R) (tadalafil),
Levitra(R) (vardenafil), oral contraceptives ("the pill") or the
contraceptive patch, Mycobutin(R) (rifabutin), inhaled Flonase(R)
(fluticasone), metronidazole, or disulfiram. Patients should talk with
their doctor about all medicines they are taking or planning to take,
including those without a prescription and herbal products.
KALETRA should not be given once-daily in combination with Sustiva(R)
(efavirenz), Viramune(R) (nevirapine), Agenerase(R) (amprenavir),
fosamprenavir, Viracept(R) (nelfinavir), phenobarbital, Dilantin(R)
(phenytoin) or Tegretol(R) carbamazepine.
Patients and/or their care providers should pay special attention to
accurate administration of the KALETRA dose to reduce the risk of
accidentally giving too much or too little medicine.
The most commonly reported side effects of moderate severity that are
thought to be drug related are abdominal pain, abnormal bowel movements,
diarrhea, feeling weak/tired, headache and nausea. Children taking KALETRA
may sometimes get a skin rash. Other side effects may occur.
Pancreatitis and liver problems, which can be fatal, have been reported
in patients receiving KALETRA. Patients should tell their doctor if they
have nausea, vomiting, or abdominal pain, which may be signs of
pancreatitis, or if they have or have had liver disease, such as hepatitis
B or C.
Some patients have had large increases in triglycerides and
cholesterol. Changes in body fat have been seen in some patients taking
anti-HIV therapy. The long-term health effects of these conditions are not
known at this time.
Diabetes and high blood sugar have occurred in patients taking protease
inhibitors, such as KALETRA.
Some patients with hemophilia have increased bleeding with protease
The effects of KALETRA on pregnant women or their unborn babies are not
known. Mothers taking KALETPage: 1 2 3 4 5 6 7 8 Related medicine technology :1
. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy2
. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP3
. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study4
. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV5
. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV6
. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females7
. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets8
. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection9
. Keppra XR(TM) Extended-Release Tablets Filed with the FDA10
. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets11
. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine